Health Care [ 7/12 ] | Biotechnology [ 47/73 ]
NASDAQ | Common Stock
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally.
The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus.
It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia.
Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 12, 25 | -0.35 Increased by +16.67% | -0.39 Increased by +10.26% |
| May 8, 25 | -0.43 Increased by +6.52% | -0.45 Increased by +4.44% |
| Mar 10, 25 | -0.39 Increased by 0.00% | -0.42 Increased by +7.14% |
| Nov 7, 24 | -0.38 Decreased by -216.67% | -0.45 Increased by +15.56% |
| Aug 6, 24 | -0.42 Increased by +12.50% | -0.46 Increased by +8.70% |
| May 7, 24 | -0.46 Increased by 0.00% | -0.40 Decreased by -15.00% |
| Mar 11, 24 | -0.39 Increased by +11.36% | -0.37 Decreased by -5.41% |
| Nov 7, 23 | -0.12 Increased by +72.73% | -0.42 Increased by +71.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 2.67 M Decreased by -23.01% | -54.10 M Decreased by -43.51% | Decreased by -2.03 K% Decreased by -86.39% |
| Mar 31, 25 | 2.35 M Decreased by -3.13% | -39.99 M Increased by +3.01% | Decreased by -1.70 K% Decreased by -0.12% |
| Dec 31, 24 | 2.08 M Decreased by -41.62% | -35.49 M Decreased by -2.85% | Decreased by -1.71 K% Decreased by -76.19% |
| Sep 30, 24 | 2.02 M Decreased by -91.45% | -34.68 M Decreased by -246.77% | Decreased by -1.71 K% Decreased by -3.95 K% |
| Jun 30, 24 | 3.46 M Decreased by -7.75% | -37.70 M Decreased by -27.70% | Decreased by -1.09 K% Decreased by -38.43% |
| Mar 31, 24 | 2.43 M Decreased by -30.64% | -41.23 M Decreased by -65.02% | Decreased by -1.70 K% Decreased by -137.92% |
| Dec 31, 23 | 3.56 M Decreased by -3.63% | -34.51 M Decreased by -27.85% | Decreased by -969.79% Decreased by -32.66% |
| Sep 30, 23 | 23.66 M Increased by +616.38% | -10.00 M Increased by +62.62% | Decreased by -42.27% Increased by +94.78% |